Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOF trial of low-dose sugammadex versus neostigmine after rocuronium in non-cardiac surgery
2016-002528-10Phase 4Terminated
- Sponsor
- Sykehuset i Vestfold
- Start
- Sep 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex, neostigmine and rocuronium (2 arms), sponsored by Sykehuset i Vestfold. Primary endpoint: Time to normalized TOF ratio. Started Sep 2016; status: terminated.
02
Drugs
Sugammadexneostigminerocuronium
Beyond the preview
Go deeper on 2016-002528-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002528-10.